Abstract：
This review seeks to understand novel avenues for eosinophilic GI disease management. Biomarkers offer a unique and non-invasive approach to tracking EoE disease progression. While no biomarkers have definitively met the diagnostic criteria for eosinophilic GI diseases, some biomarkers have been shown to be associated with disease activity. Here, we examine the potential of recently studied biomarkers.
Current research shows advancements in blood, luminal fluid, and breath testing. Particular areas of interest include mRNA analyses, protein fingerprinting, amplicon sequence variants (ASVs), T cells and IgE receptors, eosinophilic cationic proteins, cytokines, and nitric oxide exhalation. Preliminary results showed that mucosal biomarkers, directly captured from the esophagus, may reflect the best representation of biopsy-based results, in contrast to biomarkers obtained from indirect or peripheral (blood, breath) methods. However, this is based on limited clinical studies without sufficient numbers to evaluate true diagnostic accuracy. Large-scale randomized trials are needed to fully ascertain both the optimal sampling technique and the specific biomarkers that reflect diagnostic status of the disease.
Current research shows advancements in blood, luminal fluid, and breath testing. Particular areas of interest include mRNA analyses, protein fingerprinting, amplicon sequence variants (ASVs), T cells and IgE receptors, eosinophilic cationic proteins, cytokines, and nitric oxide exhalation. Preliminary results showed that mucosal biomarkers, directly captured from the esophagus, may reflect the best representation of biopsy-based results, in contrast to biomarkers obtained from indirect or peripheral (blood, breath) methods. However, this is based on limited clinical studies without sufficient numbers to evaluate true diagnostic accuracy. Large-scale randomized trials are needed to fully ascertain both the optimal sampling technique and the specific biomarkers that reflect diagnostic status of the disease.
摘要：
目的：这篇综述旨在了解嗜酸粒细胞性胃肠道疾病管理的新途径。生物标志物提供了一种独特的非侵入性方法来跟踪EoE疾病进展。虽然没有生物标志物明确符合嗜酸性胃肠道疾病的诊断标准，一些生物标志物已被证明与疾病活动有关.这里,我们检查了最近研究的生物标志物的潜力。
结果：目前的研究表明，在血液，管腔流体,和呼气测试。特别感兴趣的领域包括mRNA分析，蛋白质指纹图谱,扩增子序列变体（ASV），T细胞和IgE受体,嗜酸性阳离子蛋白，细胞因子,和一氧化氮呼气。初步结果表明，粘膜生物标志物，直接从食道捕获，可能反映基于活检的结果的最佳表示，与从间接或外周获得的生物标志物(血液，呼吸)方法。然而,这是基于有限的临床研究，没有足够的数字来评估真正的诊断准确性。需要大规模随机试验来充分确定最佳采样技术和反映疾病诊断状态的特定生物标志物。
结果：目前的研究表明，在血液，管腔流体,和呼气测试。特别感兴趣的领域包括mRNA分析，蛋白质指纹图谱,扩增子序列变体（ASV），T细胞和IgE受体,嗜酸性阳离子蛋白，细胞因子,和一氧化氮呼气。初步结果表明，粘膜生物标志物，直接从食道捕获，可能反映基于活检的结果的最佳表示，与从间接或外周获得的生物标志物(血液，呼吸)方法。然而,这是基于有限的临床研究，没有足够的数字来评估真正的诊断准确性。需要大规模随机试验来充分确定最佳采样技术和反映疾病诊断状态的特定生物标志物。
